Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | CHIEF FINANCIAL OFFICER | June 25, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date June 25, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,223 |
Ending reported balance
After 2026-06-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-25 · Exercise / conversion · Acquired 24,100 · Balance 35,323 Row 2 · 2026-06-25 · Sale · Disposed 24,100 · Balance 11,223 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.88, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2032-01-03 | Direct | 91,980 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Exercise / conversion · Disposed 24,100 · Balance 91,980 F3: Shares vested 1/48th on the first day of each month commencing February 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.88, inclusive.
F3: Shares vested 1/48th on the first day of each month commencing February 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 30, 2026 01:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,100 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001593087-26-000013 · form4-06292026_090601.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,980 Underlying: Common Stock · 24,100 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing February 1, 2022. Read SEC document |
| June 25, 2026 Filed Jun 30, 2026 01:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | SaleCommon Stock | 24,100 | $30.38 | $732,158.00 |
DisclosureSEC source: 0001593087-26-000013 · form4-06292026_090601.xml · nonDerivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,223 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.88, inclusive. Read SEC document |
| June 25, 2026 Filed Jun 30, 2026 01:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 24,100 | $3.18 | $76,638.00 |
DisclosureSEC source: 0001593087-26-000013 · form4-06292026_090601.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · derivative · entry 6 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,080 Underlying: Common Stock · 400 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing February 1, 2022. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | SaleCommon Stock | 400 | $30.00 | $12,000.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · nonDerivative · entry 4 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,223 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 400 | $3.18 | $1,272.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · nonDerivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · derivative · entry 5 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,480 Underlying: Common Stock · 500 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing February 1, 2022. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | SaleCommon Stock | 500 | $30.00 | $15,000.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · nonDerivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,223 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 500 | $3.18 | $1,590.00 |
DisclosureSEC source: 0001593087-26-000011 · form4-06242026_080603.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001593087-26-000009 · form4-05192026_040501.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on June 2, 2016 and was previously reported as covering 30,000 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing as of July 1, 2016. F1 · derivative.underlying_shares: This option was granted on June 2, 2016 and was previously reported as covering 30,000 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 3,000 | $1.39 | $4,170.00 |
DisclosureSEC source: 0001593087-26-000009 · form4-05192026_040501.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001593087-26-000007 · form4-05042026_040501.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,980 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing February 1, 2022. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | SaleCommon Stock | 25,000 | $31.70 | $792,540.00 |
DisclosureSEC source: 0001593087-26-000007 · form4-05042026_040501.xml · nonDerivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,223 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.89 to $33.19, inclusive. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 25,000 | $3.18 | $79,500.00 |
DisclosureSEC source: 0001593087-26-000007 · form4-05042026_040501.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001593087-26-000005 · form4-04012026_080406.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,980 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing February 1, 2022. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | SaleCommon Stock | 25,000 | $30.13 | $753,152.50 |
DisclosureSEC source: 0001593087-26-000005 · form4-04012026_080406.xml · nonDerivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,223 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.32, inclusive. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 25,000 | $3.18 | $79,500.00 |
DisclosureSEC source: 0001593087-26-000005 · form4-04012026_080406.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:45 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593087-26-000002 · form4-01072026_040123.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, upon vesting, one share of the Issuer's common stock in accordance with the Issuer's 2025 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units were granted on January 5, 2026 as part of the Issuer's annual equity grant to executive officers. The restricted stock units granted on January 5, 2026 vest annually at a rate of 25% commencing on February 1, 2027. Vesting is subject to the Reporting Person's continued service to the Issuer through the vesting date. F4 · derivative.expiration_date: The restricted stock units were granted on January 5, 2026 as part of the Issuer's annual equity grant to executive officers. The restricted stock units granted on January 5, 2026 vest annually at a rate of 25% commencing on February 1, 2027. Vesting is subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:45 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001593087-26-000002 · form4-01072026_040123.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-05 F2 · derivative.exercise_date: These shares of the award vest and become exercisable on the date of U.S. Food and Drug Administration approval of Deramiocel. Vesting is subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:45 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001593087-26-000002 · form4-01072026_040123.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2026, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-25-006734 · form4-03042025_070301.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on March 3, 2015 and was previously reported as covering 25,000 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: Shares vested 1/48th on the first day of each month commencing April 1, 2015. F1 · derivative.underlying_shares: This option was granted on March 3, 2015 and was previously reported as covering 25,000 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 2,500 | $1.39 | $3,475.00 |
DisclosureSEC source: 0001415889-25-006734 · form4-03042025_070301.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 6,170 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000876 · form4-01062025_070123.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,170 Underlying: Common Stock · 6,170 shares Expires 2035-01-02 F3 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2025, the date of the grant. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000876 · form4-01062025_070123.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-01-02 F2 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2025, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantCommon Stock | 3,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000876 · form4-01062025_070123.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,723 F1 · shares: Represents fully vested Restricted Stock Units as of January 2, 2025 issued for services with the Company. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 9,692 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001415889-24-000648 · form4-01042024_050101.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,692 Underlying: Common Stock · 9,692 shares Expires 2034-01-02 F2 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2024, the date of the grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001415889-24-000648 · form4-01042024_050101.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2024, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| October 23, 2023 Filed Oct 24, 2023 13:25 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 2,178 | $1.39 | $3,027.42 |
DisclosureSEC source: 0001415889-23-014485 · form4-10242023_091001.xml · nonDerivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000589 · form4-01052023_080101.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2023, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 166,980 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001415889-22-000276 · form4-01042022_090117.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,980 Underlying: Common Stock · 166,980 shares Expires 2032-01-03 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2022, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:02 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 95,693 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001104659-21-001581 · tm211849-1_4seq1.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,693 Underlying: Common Stock · 95,693 shares Expires 2031-01-04 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2021, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:33 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 120,003 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-20-071413 · tm2022128-1_4.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,003 Underlying: Common Stock · 120,003 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing March 1, 2020, until the stock option becomes fully vested and exercisable. The following stock option grant was approved by the Board on February 12, 2020 under the 2020 Plan, contingent upon stockholder approval of the 2020 Plan, which was obtained on June 5, 2020. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,178 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 12 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,178 shares Expires 2023-10-23 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F6 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $57.80 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 11 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F6 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,000 | Not disclosed Strike: $31.20 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 10 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing July 1, 2016, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,500 | Not disclosed Strike: $25.50 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 9 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $15.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 8 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 7 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 4,666 of the shares were vested on the date of grant. The remaining 9,334 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,178 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 6 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,178 Underlying: Common Stock · 2,178 shares Expires 2023-10-23 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F6 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 5 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F6 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 3,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 4 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing July 1, 2016, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 3,500 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 3 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: The shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 14,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022098 · tm208086d1_4.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 4,666 of the shares were vested on the date of grant. The remaining 9,334 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| August 08, 2019 Filed Aug 10, 2019 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001144204-19-038998 · tv527329_form4.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-08-08 F1 · derivative.exercise_date: 4,666 of the shares shall vest immediately. The remaining 9,334 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-000853 · tv482712_4.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:40 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001144204-17-000698 · v456173_4.xml · derivative · entry 1 Bergmann Anthony · CIK 0001593087 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. F1 · derivative.expiration_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| October 23, 2013 Filed Oct 24, 2023 13:25 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,178 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-23-014485 · form4-10242023_091001.xml · derivative · entry 2 Bergmann Anthony · CIK 0001593087 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,178 shares Expires 2023-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on October 23, 2013 and was previously reported as covering 21,785 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: The shares vested annually over a 4 year period commencing on November 1, 2014. F1 · derivative.underlying_shares: This option was granted on October 23, 2013 and was previously reported as covering 21,785 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.